Uterus Transplants: Identifying Stakeholders & Objections

On February 25, the Cleveland Clinic announced that the first “womb” transplant had been successfully completed in the US, using a uterus from a deceased donor. The 26-year old recipient, identified as Lindsey, joined a press conference on March 7 in a wheelchair and expressed her gratitude. On March 9, the clinic released a second media statement:  Lindsey’s uterus transplant had been removed due to a “sudden complication.” As NPR noted, the clinical trial will continue— nine women with uterine factor infertility still await the procedure in Cleveland. Their motivation to continue with the grueling, risk-laden procedure may be similar to Lindsey’s:

“I crave that experience,” she said. “I want the morning sickness, the backaches, the feet swelling. I want to feel the baby move. That is something I’ve wanted for as long as I can remember.”

The future of reproduction has never appeared so technologically complex. Amid ongoing policy debates about gene-editing embryos, and the potential spread of “3-person IVF” from the UK to the US, we’ve also seen a rapid increase of clinical trials for a revolutionary surgical procedure: womb transplants—i.e. temporary uterus transplantation into “genetic females” born without uteruses (but with working ovaries) for the purpose of enabling pregnancy for one or two genetically related IVF offspring.

An early effort at uterus transplantation was conducted in Germany in 1931 on Lili Elbe, who is historically identified as both transgender and intersex, and who died shortly thereafter. (Her story is told in The Danish Girl.)

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.